Augmenting Nrf2 signaling pathway promotes adipocyte differentiation from human embryonic stem cells.
Park MH., Gil D., Han HW., Kim JH.
Animal Study, published in Exp Cell Res (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Exp Cell Res (2026)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41620067
- DOI
- 10.1016/j.yexcr.2026.114917
Abstract (original English)
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a basic leucine zipper transcription factor best regulating cellular defense mechanisms. However, its role in human adipocyte differentiation remains poorly understood. Here, we investigated the contribution of Nrf2 to adipocyte differentiation using an in vivo teratoma model, a straightforward assay for evaluating the differentiation potential of human embryonic stem cells (hESCs). We found that enhanced Nrf2 signaling, induced by KEAP1 gene deletion in hESCs, increased both the size and area of adipocytes within teratomas. Quantitative transcriptomic analysis of teratomas (TeratoScore) and the Ingenuity Pathway Analysis indicated activation of an adipogenesis-related signaling network, as evidenced by increased expression of FABP4, PPARG, ADIPOQ, and CEBPA in KEAP1-knockout teratomas. Stepwise in vitro differentiation of hESCs into adipocytes further supported a pro-adipogenic role for Nrf2, as shown by increased lipid-droplet accumulation. Notably, we identified PAX3 as a transcriptional target associated with Nrf2 activation, suggesting a potential link between Nrf2 signaling and adipogenic regulation. Together, these findings reveal a previously underappreciated role for Nrf2 in human adipogenesis.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.